In:
The British Journal of Radiology, British Institute of Radiology, Vol. 93, No. 1106 ( 2020-02-01), p. 20190647-
Kurzfassung:
There is growing evidence supporting the use of stereotactic ablative radiotherapy (SABR) on the treatment of localised stage non-small-cell lung cancer (NSCLC). Distinctive imaging challenges are posed post-SABR treatment. Thus, it is imperative to provide guidance on assessing treatment response, especially for new adopters. This commentary is about filling a gap in response evaluation after SABR for localised NSCLC.
Materialart:
Online-Ressource
ISSN:
0007-1285
,
1748-880X
DOI:
10.1259/bjr.20190647
Sprache:
Englisch
Verlag:
British Institute of Radiology
Publikationsdatum:
2020
ZDB Id:
1468548-6